Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
Key facts
- Who runs it
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 180 people, planned
- Started
- 22 May 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- CD83-positive MSC
- regulatory MSC
- control solution
- Record updated
- 25 May 2025
Who can take part
- Age
- 0 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Age: 0-65 years old, diagnosed with sepsis
- Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines)
- Confirmed or suspected infection
Who cannot take part
- Concurrent participation in other clinical trials
- Specific medical conditions:; History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine); Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders; History of hypersensitivity or severe adverse reactions to biological products; Imminent terminal status (e.g., septic shock, life expectancy <7 days); Foreseeable risk of medical errors or disputes during hospitalization; Active drug-resistant infections; History of malignancy at screening; Pregnancy, lactation, or plans for pregnancy within the next year
- Violation of medical ethics
- Significant confounding factors likely to bias study outcomes
- Poor adherence to the study protocol
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sepsis
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.
The 2 groups in the trial
- 135 patients are infused with 1×10⁸ stem cells per sessionTreatment being tested
Treatment: CD83-positive MSC and regulatory MSC
- 45 patients are infused with equal volume of control solutionSham treatment, for comparison
Treatment: control solution
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
- Criteria questions
- Built from NCT06882811, who can take part
- Record updated
- 25 May 2025